Cover Image: May 2012 Scientific American Magazine See Inside

Return of the Clap

Gonorrhea, once a minor illness, is developing resistance to the last category of drugs that still works against it and could become untreatable















Share on Tumblr



Gonorrhea colony, as seen under a microscope Image: Juergen Berger/Photo Researchers, Inc.

Mark Pandori was worried. It was 2008, and he had just read the latest in a string of reports from Japan. The articles all described patients infected with a particular strain of gonorrhea that was less susceptible than usual to an important class of antibiotics. Pandori, director of the laboratory at the San Francisco Department of Public Health, knew that gonorrhea had become resistant to other antibiotics in past decades. Each time, the resistance seemed to arise in Asia and spread to California. He wondered if something new was heading across the Pacific.

The latest report from Japan described a test that could identify resistant strains of bacteria by isolating and amplifying the culprit gene. Pandori tried the procedure on 54 samples of gonorrhea bacteria collected that year from men in San Francisco. Five samples, or 9 percent, contained the altered gene. When he analyzed the bacteria in the lab, he found that they—like the Japanese strains—possessed partial resistance to cephalosporins, the only antibiotics that still work reliably and inexpensively against gonorrhea.

Pandori and his research partner at the time, a health department epidemiologist named Pennan Barry, were alarmed and baffled. No physicians in the state had reported any difficulties treating patients with gonorrhea. Cephalosporin resistance had apparently infiltrated California without anyone noticing. Perhaps it had started spreading across the country as well.

Last summer a surveillance network run by the Centers for Disease Control and Prevention confirmed their fears. Using a different test, the CDC demonstrated that up to 1.4 percent of 5,900 gonorrhea bacterial samples from around the U.S. had diminished susceptibility to cephalosporins, meaning they would succumb only to unusually high doses. A New England Journal of Medicine editorial published in February said the occurrence of that partial resistance increased 17 times between 2006 and 2011. “The threat of untreatable gonorrhea is emerging rapidly,” the editorial warned.

That threat is troubling for two reasons. First, gonorrhea is abundant: it is the second-most reported infectious disease in the U.S., with more than 600,000 new cases a year. Second, if untreated, it can cause widespread organ damage, pelvic inflammatory disease and infertility. Making matter worse, our current methods for tracking and controlling gonorrhea are actually contributing to the spread of resistant disease.

A Slow But Steady Spread
Gonorrhea is the first of the major sexually transmitted diseases (STDs) to tiptoe to the threshold of untreatability. True, chlamydia, which infects 426 of every 100,000 people in the country every year, is more common, and cases of syphilis, which doubled in incidence between 2000 and 2010, are growing faster. But syphilis infects only 4.5 of every 100,000 people, and neither chlamydia nor syphilis has developed significant resistance to antibiotics.

Gonorrhea, in contrast, has been developing defenses against drug treatment for decades. The latest news from Japan and California is making the disease a priority for public health planners—a status it has not known since before Alexander Fleming and the discovery of penicillin. Once antibiotics became abundant and inexpensive, gonorrhea and syphilis seemed like solved problems.

Neither infection was vanquished, however. Gonorrhea, in particular, held on by borrowing DNA from other bacteria to construct new microbiological defenses. It steadily gained resistance against entire classes of antibiotics: first the penicillins in the 1960s, then the tetracyclines in the 1980s, and Cipro and its chemical cousins, known as fluoroquinolones, in the 1990s. By 2000 the only class of drugs that could provide what public health strategies rely on—something that is inexpensive, delivered in a single dose and works well enough to obviate follow-up appointments—was the cephalosporins.



Rights & Permissions

5 Comments

Add Comment
View
  1. 1. Grumpyoleman 02:13 PM 5/11/12

    So the "gleep" is back. Thankfully, I'm too old to worry about it.

    Reply | Report Abuse | Link to this
  2. 2. stan e m 04:04 PM 5/14/12

    everyone should be tested(every six mnth) and marked if infected.Std would be extinct if this was done 50 yrs ago.

    Reply | Report Abuse | Link to this
  3. 3. jgrosay 09:46 AM 5/19/12

    In Spain, clap was called "Gota militar->Military drop", but some people having a connection with the army remark that gota militar can be also civilian and ecclesiastical.
    Those advocating screening test to detect hidden STDs must remember that the subject has been addressed before, and now there is an acceptably good image on in whom and how often screening tests are worth doing (See CDC). Even if you made, for example, HIV tests every other week in high risk people, you'll miss cases and never have a total interruption of the transmission chain, as an important window effect exists for detecting this and other transmissible diseases, and a person can be infected and pass the contagion to others in the few hours between one screening test and the next one. A change in habits would be the best approach to reduce the incidence of STDs, but taking into account how much we humans like sex, our innate preference for sexual drive over self-preservation instinct, and the previous generations' experiences about this, total erradication looks like an impossible task.

    Reply | Report Abuse | Link to this
  4. 4. carrotwax 01:32 AM 5/24/12

    As much as testing as desired, criminalization of sex with knowledge of an STD creates a disincentive for testing as is well known with HIV. Testing is a useful tool, but psychologically the ones who are most likely to contract STDs are also more likely to spread it via risky and compulsive behaviors.

    Furthermore, science is one thing but business models are another. Profit motive is what often determines research directions, not health or utilitarian goals. Vaccines can create massive benefit, but they are only bought once. I would like to see more vaccine research myself, but in an ever increasing profit driven system, there is likely going to be only limit research.

    Reply | Report Abuse | Link to this
  5. 5. missing link 07:07 AM 12/26/12

    Hi,

    I found this website to have a lot of information on Gonorrhea and other std's so I hope it helps some of you.
    http://www.the-clap.com

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

Tweets could not be retrieved at this time

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Return of the Clap: Scientific American Magazine

X
Scientific American MIND iPad

Tap into your MIND

Get Both Print & Tablet Editions for one low price!

Subscribe Now >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X